Endonovo Therapeutics (ENDV) Current Assets (2016 - 2023)
Endonovo Therapeutics has reported Current Assets over the past 13 years, most recently at $35504.0 for Q3 2023.
- Quarterly results put Current Assets at $35504.0 for Q3 2023, up 47.42% from a year ago — trailing twelve months through Sep 2023 was $35504.0 (up 47.42% YoY), and the annual figure for FY2022 was $15822.0, down 83.32%.
- Current Assets for Q3 2023 was $35504.0 at Endonovo Therapeutics, down from $72833.0 in the prior quarter.
- Over the last five years, Current Assets for ENDV hit a ceiling of $585900.0 in Q2 2019 and a floor of $5945.0 in Q2 2022.
- Median Current Assets over the past 5 years was $46187.0 (2020), compared with a mean of $77498.3.
- Biggest five-year swings in Current Assets: plummeted 98.37% in 2020 and later skyrocketed 1125.11% in 2023.
- Endonovo Therapeutics' Current Assets stood at $62555.0 in 2019, then dropped by 26.17% to $46187.0 in 2020, then surged by 105.37% to $94855.0 in 2021, then crashed by 83.32% to $15822.0 in 2022, then soared by 124.4% to $35504.0 in 2023.
- The last three reported values for Current Assets were $35504.0 (Q3 2023), $72833.0 (Q2 2023), and $95172.0 (Q1 2023) per Business Quant data.